Biogen Inc. (NASDAQ: BIIB) reported its financial results for the quarter ended March 31, 2020 today.
Biogen posted a 1% decline in earnings for the first quarter of 2020 due to higher costs and expenses despite a 1% rise in the top-line. The company continued to develop and expand its pipeline, including making good progress toward the US regulatory filing for aducanumab, as well as bolstering its efforts in gene therapy through a collaboration with Sangamo.
The company believes that the magnitude and uncertainty surrounding the COVID-19 pandemic clearly introduce unanticipated and potentially unquantifiable risks to its business and results over the near-term. While Biogen does expect there will be some impact on timelines for certain of its clinical programs, it still expects the vast majority of the 10 remaining near-term readouts to occur before the end of 2021.
Past Performance
Most Popular
Earnings reports to watch for the week of Nov. 23
After starting the week on a positive note, major stock indexes witnessed volatility and slipped mid-week. Meanwhile, the S&P 500 index regained a part of the lost momentum and closed
US retailers and the holiday season – TJX Companies (TJX)
The TJX Companies Inc. (NYSE: TJX) saw sales slightly drop during the third quarter of 2021 while earnings benefited from lower tax rates. Open-only comp store sales were down 5%
Usio: An under-the-radar fintech firm
Value investors have long viewed the fintech industry as a gold mine of opportunities in the years to come, with payment processing services carrying a fair share of interest. Those